Davis's Drug Guide
Avalide 300/12.5
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Avalide 300/12.5." Davis's Drug Guide, 18th ed., F.A. Davis Company, 2023. www.drugguide.com/ddo/view/Davis-Drug-Guide/61038/all/Avalide_300_12_5.
Vallerand AHA, Sanoski CAC, Quiring CC. Avalide 300/12.5. Davis's Drug Guide. F.A. Davis Company; 2023. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/61038/all/Avalide_300_12_5. Accessed June 3, 2023.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Avalide 300/12.5. In Davis's Drug Guide (18th ed.). F.A. Davis Company. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/61038/all/Avalide_300_12_5
Vallerand AHA, Sanoski CAC, Quiring CC. Avalide 300/12.5 [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2023. [cited 2023 June 03]. Available from: https://www.drugguide.com/ddo/view/Davis-Drug-Guide/61038/all/Avalide_300_12_5.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Avalide 300/12.5
ID - 61038
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://www.drugguide.com/ddo/view/Davis-Drug-Guide/61038/all/Avalide_300_12_5
PB - F.A. Davis Company
ET - 18
DB - Davis's Drug Guide
DP - Unbound Medicine
ER -